Laxxon Medical Unveils Non-Invasive 3D Printed Oral GLP-1 Alternative

Laxxon Medical has revealed its progress on LXM.2, a 3D printed oral tablet designed to treat obesity in adults and children aged 12 and above. LXM.2 is built using SPID®-Technology, which integrates a glucagon-like peptide-1 (GLP-1) receptor agonist with a permeation enhancer to boost bioavailability. This innovative approach has been made possible through Laxxon Medical's advanced screen printing platform.

Dr. Achim Schneeberger, Chief Scientific Officer at Laxxon, highlighted the challenges of using conventional manufacturing methods for such combinations. He explained that the degradation of GLP-1s in the gastrointestinal tract necessitates protection and enhancement for better absorption. Traditional techniques like direct compression or granulation have struggled to effectively incorporate permeation enhancers and apply enteric coatings. However, SPID®-Technology allows for precise dosing and the creation of solid oral medications with the necessary hardness and low friability.

The active pharmaceutical ingredient (API) in LXM.2 has already received FDA approval for use in both adults and pediatric patients over the age of 12 who are dealing with obesity. The development of LXM.2 is being pursued via the 505(b)2 regulatory pathway, with targeted submission for a New Drug Application (NDA) set for early 2027.

Helmut Kerschbaumer, CEO of Laxxon Medical, emphasized that LXM.2 could revolutionize obesity treatment. He noted that while injectable medications are effective, they can be inconvenient for some patients. An oral alternative like LXM.2 could enhance ease of use and adherence, potentially enabling more patients to manage their weight successfully and achieve long-term health benefits. The 505(b)2 pathway could expedite the process of making LXM.2 available to patients.

Laxxon Medical is actively seeking partners or licensees for LXM.2 and will be presenting at the BIO conference in San Diego from June 3-8, 2024.

Laxxon Medical is a pioneering pharma-technology company that utilizes SPID®, a novel 3D screen printing technology, to develop a new generation of advanced pharmaceuticals. This technology enables innovative drug delivery solutions, fast-tracked market access, and extensive intellectual property protection, creating significant opportunities for partners and life-changing outcomes for patients. The company's pipeline includes collaborations with major pharmaceutical companies, biotech firms, and research universities, along with 13 in-house Advanced Patented Generics products. Laxxon holds 150 patents and patent applications, encompassing over 3,000 patent claims.